Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Marinus Pharmaceuticals (MRNS) PT Raised to $24.50 at Ladenburg Thalmann
March 6, 2019 1:35 PM ESTLadenburg Thalmann analyst Michael Higgins raised the price target on Marinus Pharmaceuticals (NASDAQ: MRNS) to $24.50 (from $22.00) while maintaining a Buy rating.
... More